Telengana unrest takes toll on AP pharma industry

Image
Press Trust of India Hyderabad
Last Updated : Jan 21 2013 | 12:54 AM IST

Pharma companies in Andhra Pradesh say they are losing heavily due to the Telengana unrest in the State.

Firms in the state could not manufacture products worth nearly Rs 400 crore in the past ten days due to the agitations and bandhs called by pro and anti Telengana organisations, said M Narayana Reddy, former president, Bulk Drug Manufacturers Association (BDMA).

He said pharma units had to be closed two days before the day of a bandh. "Pharma Manufacturing process involves so many continuous processes, and we cannot stop just like that unlike any other manufacturing process," Reddy said.

GlaxoSmithKline (GSK) halted operations in its unit near Rajahmundry today. The Japanese Eisai Co Ltd, manufacturing and marketing chemicals, food additives, machinery and equipment for pharmaceutical production, postponed opening of its manufacturing plant in Vizag, scheduled for today.

Reddy said foreign buyers are apprehensive about the situation in the state. "Business runs on trust. Even a slightest doubt, in their minds, may create a blockade for investments in the State," he said.

Reddy said states like Gujarat may try to take advantage of the situation.

After the Union Home Minister P Chidambaram announced that the process of formation of Telangana State would be initiated, there has been a series of agitations in protest in the coastal and Rayalaseema regions of the state.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 12 2009 | 4:48 PM IST

Next Story